Adding nab-paclitaxel to gemcitabine and cisplatin does not improve outcomes in newly diagnosed, advanced biliary tract cancers, a phase 3 trial suggests.
Adding bevacizumab to treatment with trifluridine and tipiracil improved outcomes in patients with refractory metastatic colorectal cancer in the phase 3 SUNLIGHT trial.
The addition of transarterial chemoembolization to adjuvant sorafenib improved outcomes for patients with hepatocellular carcinoma and portal vein tumor thrombosis in a phase 2 trial.
Patients with gastric cancer or dysplasia who underwent endoscopic submucosal dissection at very low-volume centers had a higher risk of adverse outcomes.